Some questions for people that have more knowledge than I do:
- Can API holdings delist pharmeasy even with 66% shareholders? What happens to the 34% shareholders then? Where do their demat account shares go? My understanding is that these shares would remain in the demat but would not be tradable if the delisting happens.
- From the little I have been able to gather looking at Siddarth shah’s public comments on this deal it looks unlikely that Thyrocare would be allowed to function as a separate entity for long. It does not make sense for for them. Thus, a thyrocare investor mentally be prepared (imho) to become a API Holdings (PE) shareholder instead (in K years).
Disc: evaluating whether it makes sense to invest in Thyrocare.